ILLUMINA INC (ILMN)
US4523271090 - Common Stock
ILMN gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 59 industry peers in the Life Sciences Tools & Services industry. The financial health of ILMN is average, but there are quite some concerns on its profitability. ILMN is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year ILMN was profitable.
In the past year ILMN had a positive cash flow from operations.
In multiple years ILMN reported negative net income over the last 5 years.
Each year in the past 5 years ILMN had a positive operating cash flow.
1.2 Ratios
The Return On Assets of ILMN (-11.47%) is comparable to the rest of the industry.
ILMN has a Return On Equity (-20.19%) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -11.47% | ||
| ROE | -20.19% | ||
| ROIC | N/A |
ROA(3y)-14.14%
ROA(5y)-4.02%
ROE(3y)-26.62%
ROE(5y)-8.83%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ILMN has a Gross Margin of 60.95%. This is amongst the best in the industry. ILMN outperforms 84.75% of its industry peers.
In the last couple of years the Gross Margin of ILMN has declined.
ILMN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 60.95% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.6%
GM growth 5Y-2.46%
2. Health
2.1 Basic Checks
ILMN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ILMN has more shares outstanding
ILMN has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ILMN has an improved debt to assets ratio.
2.2 Solvency
ILMN has an Altman-Z score of 3.24. This indicates that ILMN is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.24, ILMN is in the better half of the industry, outperforming 62.71% of the companies in the same industry.
ILMN has a debt to FCF ratio of 5.28. This is a neutral value as ILMN would need 5.28 years to pay back of all of its debts.
ILMN's Debt to FCF ratio of 5.28 is fine compared to the rest of the industry. ILMN outperforms 74.58% of its industry peers.
A Debt/Equity ratio of 0.26 indicates that ILMN is not too dependend on debt financing.
The Debt to Equity ratio of ILMN (0.26) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 5.28 | ||
| Altman-Z | 3.24 |
ROIC/WACCN/A
WACC11.81%
2.3 Liquidity
A Current Ratio of 1.66 indicates that ILMN should not have too much problems paying its short term obligations.
ILMN has a Current ratio of 1.66. This is in the lower half of the industry: ILMN underperforms 77.97% of its industry peers.
ILMN has a Quick Ratio of 1.29. This is a normal value and indicates that ILMN is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.29, ILMN is doing worse than 76.27% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.66 | ||
| Quick Ratio | 1.29 |
3. Growth
3.1 Past
The earnings per share for ILMN have decreased strongly by -58.96% in the last year.
The earnings per share for ILMN have been decreasing by -31.38% on average. This is quite bad
The Revenue has decreased by -1.72% in the past year.
ILMN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.21% yearly.
EPS 1Y (TTM)-58.96%
EPS 3Y-42.18%
EPS 5Y-31.38%
EPS growth Q2Q0%
Revenue 1Y (TTM)-1.72%
Revenue growth 3Y11.62%
Revenue growth 5Y6.21%
Revenue growth Q2Q3.6%
3.2 Future
The Earnings Per Share is expected to grow by 61.67% on average over the next years. This is a very strong growth
ILMN is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.01% yearly.
EPS Next Y3.7%
EPS Next 2Y69.56%
EPS Next 3Y60.45%
EPS Next 5Y61.67%
Revenue Next Year0.68%
Revenue Next 2Y4.26%
Revenue Next 3Y5.57%
Revenue Next 5Y10.01%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
ILMN is valuated quite expensively with a Price/Earnings ratio of 139.26.
Based on the Price/Earnings ratio, ILMN is valued a bit cheaper than the industry average as 62.71% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 25.25. ILMN is valued rather expensively when compared to this.
ILMN is valuated quite expensively with a Price/Forward Earnings ratio of 134.29.
ILMN's Price/Forward Earnings is on the same level as the industry average.
ILMN is valuated expensively when we compare the Price/Forward Earnings ratio to 21.67, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 139.26 | ||
| Fwd PE | 134.29 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ILMN is valued a bit cheaper than 62.71% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, ILMN is valued a bit cheaper than the industry average as 62.71% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 68.43 | ||
| EV/EBITDA | 51.81 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as ILMN's earnings are expected to grow with 60.45% in the coming years.
PEG (NY)37.6
PEG (5Y)N/A
EPS Next 2Y69.56%
EPS Next 3Y60.45%
5. Dividend
5.1 Amount
No dividends for ILMN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ILLUMINA INC
NASDAQ:ILMN (4/25/2024, 2:32:37 PM)
121.16
-1.71 (-1.39%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap19.30B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 139.26 | ||
| Fwd PE | 134.29 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)37.6
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -11.47% | ||
| ROE | -20.19% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 60.95% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.66 | ||
| Quick Ratio | 1.29 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-58.96%
EPS 3Y-42.18%
EPS 5Y
EPS growth Q2Q
EPS Next Y3.7%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-1.72%
Revenue growth 3Y11.62%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y